Page 273 - ebook HCC

GENEVA, SWITZERLANDA, SWITZERLAND
PROGRAMME AND ABSTRACTSAND ABSTRACTS
EASL HCC SUMMITHCC SUMMIT
270 PROGRAMME GENEV EASL 271
270
271
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number C48
RADIOEMBOLIZATION WITH YTTRIUM-90
MICROSPHERES IN TREATMENT OF ADVANCED
HEPATOCELLULAR CARCINOMA WITH
VASCULAR INVASION; FIRST EGYPTIAN PILOT
STUDY

Ahmed El Dorry , Amr El Fouly , Mahmoud El Metenei , Mohamed S. Ghazy , Results: In this prospective pilot study; 52 advanced HCC patients, Child A liver cirrhosis
1
2
3
1
Mohamed El Garieb , Khalid Taleeb , Emad El Kaddi , Mohamed K. Shaker and are representing 61%, vascular invasion in 82%, advanced HCC BCLC stage “C” in 90%
5
6
4
1
Hepatoma Group - Ain Shams University Hospitals - Egypt with median observation period of 10 months, the time to radiological progression is 10.8
1 Intervention Radiology, Ain Shams University, Hepatology, Egyptian Atomic Energy months (95% CI: 4.9 – 16.8), the overall median survival is 12.1 months (95% CI 5.6
2
4
3
Authority, Liver Transplant Surgery, Ain Shams University, Nuclear Medicine, – 18.7 mons). Partial radiological response rate was achieved in is 75% in respect to
5 Intervention Radiology, International Medical Center, RECIST criteria respectively. The main post-therapeutic AE’s were 45% transient fatigue
6 Tropical Medicine, Ain Shams University, Cairo, Egypt syndrome, 29% transient lymphopenia, and hyperbilirubinemia 12% with has grade 3-4
toxicity; during the first 4 weeks after therapy but neither visceral nor pulmonary toxicity
Corresponding author’s e-mail: amrfouly@yahoo.com had been reported.
Conclusion: Yttrium-90 is safe and effective treatment in patients with advanced HCC,
Introduction: The Barcelona Clinic of Liver Cancer (BCLC) considered portal vein especially it has trends to improve overall survival and time to progression of HCC,
thrombosis in cirrhotic patients as the main obstacle against locoregional therapy among furthermore randomized control trials with and against systemic therapy is warranted.
patients with advanced Hepatocellular Carcinoma (HCC). Sorafenib is considered the first-
line therapy for advanced HCCs, but in case of disease progression or intolerable adverse
events there is no available second-line therapy. The selective intrahepatic application of
Yttrium-90 microspheres is a new adjuvant technology in recent intervention radiology,
because they are concentrated in tumor bed and sequentially has a high concentrated
dose of local directed radiation with least local and systemic adverse effects.
CLINICAL POSTER ABSTRACTS with vascular invasion. CLINICAL POSTER ABSTRACTS
Aims: Our Aim is to clarify the safety and efficacy of radioembolization in HCC especially
Methodology: Between 04/2009 and 01/2013, Sixty Four patients with advanced HCC
especially with portal vein invasion not candidates for surgical or curative options, had
been treated by selective internal radiotherapy (SIRT) with Yttrium-90 microspheres. All
patients had chronic liver disease with Child-Pugh points range between 5-7 points. The
treatment was performed in a lobar fashion through the right or left hepatic artery. Post
therapeutic assessment had been evaluated clinically in respect to WHO performance
status, tumor marker (AFP) and radiological response according to modified RECIST
criteria in sequential CT-scans. Safety of this technique has been evaluated according to
CTCv3 (Common Terminology Criteria version 3).